(Q46685348)

English

Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers

scientific article published on 18 August 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Salmonella enterica

0 references

typhoid vaccine

1 reference

based on heuristic

inferred from title

author name string

B D Kirkpatrick

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Robin McKenzie

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

J Patrick O'Neill

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Catherine J Larsson

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

A Louis Bourgeois

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Janet Shimko

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Matthew Bentley

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Jill Makin

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Steve Chatfield

9

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Zoë Hindle

10

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Christine Fidler

11

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Brad E Robinson

12

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Cassandra H Ventrone

13

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Nivedita Bansal

14

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Colleen M Carpenter

15

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Deborah Kutzko

16

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Sandra Hamlet

17

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Casey LaPointe

18

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

David N Taylor

19

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

language of work or name

0 references

publication date

18 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

24

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

116-123

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Multidrug-resistant Salmonella typhi: a worldwide epidemic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Enteric fever treatment failures: a global concern

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Widespread occurrence of multiple drug-resistantSalmonella typhi in India

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Live attenuated Salmonella: a paradigm of mucosal vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Optimization of Salmonella enterica serovar typhi DeltaaroC DeltassaV derivatives as vehicles for delivering heterologous antigens by chromosomal integration and in vivo inducible promoters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Induction of protective immunity against Streptococcus mutans colonization after mucosal immunization with attenuated Salmonella enterica serovar typhimurium expressing an S. mutans adhesin under the control of in vivo-inducible nirB promoter.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Towards new immunotherapies: targeting recombinant cytokines to the immune system using live attenuated Salmonella.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Enteric pathogens as vaccine vectors for foreign antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Genetic characteristics of the Salmonella typhi strain Ty21a vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Specific immunoglobulin-secreting human blood cells after peroral vaccination against Salmonella typhi.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Characterization of a post-translational modification of Campylobacter flagellin: identification of a sero-specific glycosyl moiety.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Considerations regarding mass vaccination against typhoid fever as an adjunct to sanitation and public health measures: potential use in an epidemic in Tajikistan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Bacteremic typhoid fever in children in an urban slum, Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Oral immunization with a Salmonella typhimurium vaccine vector expressing recombinant enterotoxigenic Escherichia coli K99 fimbriae elicits elevated antibody titers for protective immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

based on heuristic

inferred from DOI database lookup

Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of coexpressed cholera toxin A2 and B subunits.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

based on heuristic

inferred from DOI database lookup

Progress in vaccines against typhoid fever

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2005.08.008

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16140433

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46685348&oldid=2126810005"